31 vipph Westchester Soccer Club Debuts New Home Kit to Kick Off Upcoming SeasonMy experience with the coyote the other day got me curious about the species. As I mentioned last week, coyotes are fairly common throughout all of New England these days, but I’ve seen them on only a few occasions. The recent sighting was my closest encounter with a coyote to date and the only one so far that afforded a photo opp. As is often the case, once I get a decent photo of a species, I do a deep dive into its life history. Here are some interesting facts (at least I found them interesting) about the eastern coyote, gleaned from several sources on the Internet. Eastern coyotes are much larger than western coyotes, up to twice the size, according to the N.H. Fish and Game Department, and range in color from “silvery gray to grizzled, brownish red.” Based on the one I saw the other week, I am not surprised to learn that eastern coyotes are bigger than their western relatives. “My” coyote was big and sturdy looking with a rich, thick coat and bushy tail. It was the opposite of the sickly, scraggly-looking animal that many may imagine when picturing a coyote. Eastern coyotes have a genetic mix of coyote, domestic dog and wolf, hence their larger size. “Recent genetic research has attributed the eastern coyote’s larger size and unique behavioral characteristics to interbreeding with Eastern Canadian wolves,” N.H. Fish and Game writes on its website. Coyotes are a relatively new species to the region. Although it is unclear whether they are historically native to the region, N.H. Fish and Game states that there were no coyotes present in New Hampshire in the late 1800s, and the first verified account was in 1944. They gradually spread throughout the state and are now found in every county. I can recall two incidents, one in Errol near Umbagog Lake and one in Pittsburg near the Canadian border, where I was alone in the woods and heard a pack of coyotes howling and yipping back and forth. Both incidents were in the middle of the day. The frantic and loud nature of the communication was simultaneously unsettling and exhilarating. I never caught a glimpse of the pack in either case. “Coyotes are capable of many distinct vocalizations — the yipping of youngsters, barks to indicate a threat, long howls used to bring pack members together, and group yip-howls issued when pack members reunite,” N.H. Fish and Game writes. Coyotes, contrary to what some believe, do not howl or otherwise vocalize after making a kill, as that could draw the attention of other predators. “The last thing coyotes would want to do is attract competing coyotes or other predators to their hard-earned kill or to announce their presence to any nearby prey before a hunt. Their howls, yips, and barks likely have more to do with cementing family bonds and defending/establishing territory,” writes the National Park Service on its website. Coyotes have a varied diet that includes rodents, squirrels, rabbits and hares, insects, fruit, and even carrion and garbage. They have also been known to take house cats and small dogs. In other words, they have adapted well to living among people. “As for your safety, coyotes pose little risk to people,” N.H. Fish and Game writes. Controlling coyotes has proven to be a difficult task, as they are smart, elusive and produce a lot of offspring. Hunting season is open all year for shooting in New Hampshire, and there is also a five-month trapping season. It is illegal to use poison as a means of control. “Few animal species have been persecuted and hunted down with as much vigor and vitriol as the coyote in the United States,” the National Park Service writes. I’ve never lost a pet to a coyote, and I don’t have a farm to protect, so I like the idea of coyotes living among us. The resourceful predators add mystery, verve and diversity to New England’s wild landscape.World Series vision that got Nathan Eovaldi to the Rangers is the same one that got him to re-sign

BNP Paribas Financial Markets lifted its stake in Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ) by 824.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 111,775 shares of the life sciences company’s stock after acquiring an additional 99,685 shares during the quarter. BNP Paribas Financial Markets owned 0.14% of Integra LifeSciences worth $2,031,000 as of its most recent filing with the Securities & Exchange Commission. Several other hedge funds have also recently made changes to their positions in IART. Cooke & Bieler LP lifted its holdings in Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after acquiring an additional 388,710 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Integra LifeSciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after purchasing an additional 12,766 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Integra LifeSciences by 15.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after purchasing an additional 125,620 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in shares of Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock worth $24,925,000 after buying an additional 335,557 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in Integra LifeSciences by 90.9% during the second quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company’s stock valued at $17,436,000 after buying an additional 291,326 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors. Integra LifeSciences Stock Up 1.0 % Shares of IART opened at $24.10 on Friday. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $1.86 billion, a PE ratio of -267.75, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The business’s 50 day moving average is $21.44 and its 200 day moving average is $23.88. Insider Activity In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Company insiders own 3.10% of the company’s stock. Analysts Set New Price Targets Several research analysts have recently weighed in on the stock. Truist Financial dropped their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. Morgan Stanley initiated coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target for the company. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Citigroup boosted their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $23.00. Read Our Latest Report on Integra LifeSciences Integra LifeSciences Profile ( Free Report ) Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. See Also Five stocks we like better than Integra LifeSciences What Are Some of the Best Large-Cap Stocks to Buy? Fast-Growing Companies That Are Still Undervalued What Makes a Stock a Good Dividend Stock? Top Cybersecurity Stock Picks for 2025 Bank Stocks – Best Bank Stocks to Invest In Archer or Joby: Which Aviation Company Might Rise Fastest? Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. ( NASDAQ:IART – Free Report ). Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter .

Forteza kicks six field goals to lift Laval to 22-17 win over Laurier in Vanier CupNEW YORK (AP) — Angelina Jolie never expected to hit all the notes. But finding the breath of Maria Callas was enough to bring things out of Jolie that she didn’t even know were in her. “All of us, we really don’t realize where things land in our body over a lifetime of different experiences and where we hold it to protect ourselves,” Jolie said in a recent interview. “We hold it in our stomachs. We hold it in our chest. We breathe from a different place when we’re nervous or we’re sad. “The first few weeks were the hardest because my body had to open and I had to breathe again,” she adds. “And that was a discovery of how much I wasn’t.” In Pablo Larraín’s “Maria,” which Netflix released in theaters Wednesday before it begins streaming on Dec. 11, Jolie gives, if not the performance of her career, then certainly of her last decade. Beginning with 2010’s “In the Land of Blood and Honey,” Jolie has spent recent years directing films while prioritizing raising her six children. “So my choices for quite a few years were whatever was smart financially and short. I worked very little the last eight years,” says Jolie. “And I was kind of drained. I couldn’t for a while.” But her youngest kids are now 16. And for the first time in years, Jolie is back in the spotlight, in full movie-star mode. Her commanding performance in “Maria” seems assured of bringing Jolie her third Oscar nomination. (She won supporting actress in 2000 for “Girl, Interrupted.”) For an actress whose filmography might lack a signature movie, “Maria” may be Jolie's defining role. Jolie's oldest children, Maddox and Pax, worked on the set of the film. There, they saw a version of their mother they hadn't seen before. “They had certainly seen me sad in my life. But I don’t cry in front of my children like that,” Jolie says of the emotion Callas dredged up in her. “That was a moment in realizing they were going to be with me, side by side, in this process of really understanding the depth of some of the pain I carry.” Jolie, who met a reporter earlier this fall at the Carlyle Hotel, didn't speak in any detail of that pain. But it was hard not to sense some it had to do with her lengthy and ongoing divorce from Brad Pitt, with whom she had six children. Just prior to meeting, a judge allowed Pitt’s remaining claim against Jolie, over the French winery Château Miraval, to proceed. On Monday, a judge ruled that Pitt must disclose documents Jolie’s legal team have sought that they allege include “communications concerning abuse.” Pitt has denied ever being abusive. The result of the U.S. presidential election was also just days old, though Jolie — special envoy for the United Nations Refugee Agency from 2012 to 2022 – wasn’t inclined to talk politics. Asked about Donald Trump’s win , she responded, “Global storytelling is essential,” before adding: “That’s what I’m focusing on. Listening. Listening to the voices of people in my country and around the world.” Balancing such things — reports concerning her private life, questions that accompany someone of her fame — is a big reason why Jolie is so suited to the part of Callas. The film takes place during the American-born soprano’s final days. (She died of a heart attack at 53 in 1977.) Spending much of her time in her grand Paris apartment, Callas hasn’t sung publicly in years; she’s lost her voice. Imprisoned by the myth she’s created, Callas is redefining herself and her voice. An instructor tells her he wants to hear “Callas, not Maria." The movie, of course, is more concerned with Maria. It’s Larrain’s third portrait of 20th century female icon, following “Jackie” (with Natalie Portman as Jacqueline Kennedy) and “Spencer” (with Kristen Stewart as Princess Diana). As Callas, Jolie is wonderfully regal — a self-possessed diva who deliciously, in lines penned by screenwriter Steven Knight, spouts lines like: “I took liberties all my life and the world took liberties with me.” Asked if she identified with that line, Jolie answered, “Yeah, yeah.” Then she took a long pause. “I’m sure people will read a lot into this and there’s probably a lot I could say but don’t want to feed into,” Jolie eventually continues. “I know she was a public person because she loved her work. And I’m a public person because I love my work, not because I like being public. I think some people are more comfortable with a public life, and I’ve never been fully comfortable with it.” When Larraín first approached Jolie about the role, he screened “Spencer” for her. That film, like “Jackie” and “Maria,” eschews a biopic approach to instead intimately focus on a specific moment of crisis. Larraín was convinced Jolie was meant for the role. “I felt she could have that magnetism,” Larraín says. “The enigmatic diva that’s come to a point in her life where she has to take control of her life again. But the weight of her experience, of her music, of her singing, everything, is on her back. And she carries that. It’s someone who’s already loaded with a life that’s been intense.” “There’s a loneliness that we both share,” Jolie says. “That’s not necessarily a bad thing. I think people can be alone and lonely sometimes, and that can be part of who they are.” Larraín, the Chilean filmmaker, grew up in Santiago going to the opera, and he has long yearned to bring its full power and majesty to a movie. In Callas, he heard something that transfixed him. “I hear something near perfection, but at the same time, it’s something that’s about to be destroyed,” Larraín says. “So it’s as fragile and as strong as possible. It lives in both extremes. That’s why it’s so moving. I hear a voice that’s about to be broken, but it doesn’t.” In Callas’ less perfect moments singing in the film, Larraín fuses archival recordings of Callas with Jolie’s own voice. Some mix of the two runs throughout “Maria.” “Early in the process,” Jolie says, “I discovered that you can’t fake-sing opera.” Jolie has said she never sang before, not even karaoke. But the experience has left her with a newfound appreciation of opera and its healing properties. “I wonder if it’s something you lean into as you get older,” Jolie says. “Maybe your depth of pain is bigger, your depth of loss is bigger, and that sound in opera meets that, the enormity of it.” If Larraín’s approach to “Maria” is predicated on an unknowingness, he's inclined to say something similar about his star. “Because of media and social media, some people might think that they know a lot about Angelina,” he says. “Maria, I read nine biographies of her. I saw everything. I read every interview. I made this movie. But I don’t think I would be capable of telling you who she was us. So if there’s an element in common, it’s that. They carry an enormous amount of mystery. Even if you think that you know them, you don’t.” Whether “Maria” means more acting in the future for Jolie, she's not sure. “There's not a clear map,” she says. Besides, Jolie isn't quite ready to shake Callas. “When you play a real person, you feel at some point that they become your friend,” says Jolie. “Right now, it’s still a little personal. It’s funny, I’ll be at a premiere or I’ll walk into a room and someone will start blaring her music for fun, but I have this crazy internal sense memory of dropping to my knees and crying.” Jake Coyle, The Associated PressFyodor Lukyanov: How likely is a nuclear exchange over Ukraine?

Are you tracking your health with a device? Here’s what could happen with the data

Zebra Technologies' chief accounting officer sells $75,979 in stock

Ayatollah Khamenei says all Israeli political and military captains must face justice

NVIDIA Co. (NASDAQ:NVDA) is Riggs Asset Managment Co. Inc.’s 4th Largest PositionAP News Summary at 1:32 p.m. ESTAnalysis: How McLaren went from “chaos” to F1 champions

Batcho scores 19 in Louisiana Tech's 78-69 victory over Eastern Kentucky

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Fmr LLCBerry Petroleum stock hits 52-week low at $3.9 amid downturnLINCOLN — Three things we learned and three things we still don't know about the Huskers coming out of Nebraska's win over Wisconsin. * * * 1. The Huskers are headed back to a bowl game for the first time since 2016. Shall we reacquaint you with the most likely options? There’s the Dec. 26 Guaranteed Rate Bowl in Phoenix vs. a Big 12 team, the Dec. 26 Quick Lane Bowl in Detroit vs. the MAC champion, the Dec. 28 Pinstripe Bowl vs. an ACC team or, if NU managed to upset Iowa, the Dec. 30 Music City Bowl in Nashville vs. a SEC team. 2. Nebraska finally turned the first carries over to the best running back — Emmett Johnson. And the sophomore from Minneapolis delivered with three carries for 22 yards and a catch on NU’s opening drive. While Johnson may have options in the transfer portal, the Huskers should make NIL and revenue-sharing efforts to keep him. Johnson seems to fit the Dana Holgorsen system. 3. Even the best special teams units make mistakes. Wisconsin is ranked in ESPN’s top 20 of special teams units, but the Badgers allowed both a 45-yard kickoff return to start the game and, later, missed a 34-yard field goal after a delay-of-game penalty. Wisconsin also hammered a kickoff out of bounds, too. Uncharacteristic errors. 1. How quickly Nebraska can lock up Dana Holgorsen as the full-time, long-haul offensive coordinator. For NU’s first half alone, when the Huskers knocked out drives of 55, 80 and 76 yards for touchdowns, Holgorsen deserves a little extra. NU quarterback Dylan Raiola looked awfully sleek, too, completing 17 of 22 passes in the first half. The Jahmal Banks the Huskers hoped to get all season may have disappeared for a bit, but he returned Saturday with clutch third down catches and good blocks. Holgo lit a fire in that offense. 2. Whether the Huskers’ defense can handle the Hawkeye run game on a short week. NU has generally struggled to do so, and this is Iowa’s best rush attack in years. Wisconsin wanted to pound the ball at the Huskers with a diet of power plays, but had only intermittent success and a costly end-of-first-half fumble. Nebraska’s secondary is beat up and a little discombobulated, but Iowa’s starting quarterback, Jackson Stratton, may not be up for that task. 3. How many of those non-senior seniors who walked on Senior Day plan to return. Alongside super seniors like Ty Robinson and Isaac Gifford — those guys are done — you saw players like Stefon Thompson, Elijah Jeudy and Nate Boerkircher making the Senior Day walk, as well. Javin Wright did not walk because he’ll consider applying for a seventh year with a medical redshirt. Get local news delivered to your inbox!

Are you tracking your health with a device? Here’s what could happen with the data